Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4761655 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL589886 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL14134551 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL588927 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL9917631 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL24974550 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL12081887 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL22444953 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL21224008 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL31671113 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025081242-A1 | EXTRACELLULAR VESICLE COMPOSITIONS AND USES THEREOF | INOVIQ Ltd (AU) | 2025-04-24 | — | — | WO | disclosed |
| CN-118662655-A | Compound, pharmaceutical composition, preparation method and application thereof | 安迪高生物制药有限公司 | 2024-09-20 | — | — | CN | disclosed |
| EP-3197501-B1 | BIOLOGICAL MATERIALS AND USES THEREOF | ANTIKOR BIOPHARMA LTD (GB) | 2024-04-10 | — | — | EP | disclosed |
| US-20220233706-A1 | BIOLOGICAL MATERIALS AND USES THEREOF | ANTIKOR BIOPHARMA LTD (GB) | 2022-07-28 | — | — | US | disclosed |
| CN-105801686-B | Insulin-oligomer conjugates, formulations and uses thereof | 比奥孔有限公司 | 2020-04-07 | — | — | CN | disclosed |
| EP-2626368-B1 | Insulin-oligomer conjugates, formulations and uses thereof | BIOCON LTD (IN) | 2016-12-21 | — | — | EP | disclosed |
| EP-2626368-B1 | Insulin-oligomer conjugates, formulations and uses thereof | BIOCON LTD (IN) | 2016-12-21 | — | — | EP | disclosed |
| US-9101596-B2 | Cation complexes of insulin compound conjugates, formulations and uses thereof | BIOCON LIMITED (IN) | 2015-08-11 | — | — | US | disclosed |
| US-9102758-B2 | Insulin-oligomer conjugates, formulations and uses thereof | BIOCON LIMITED (IN) | 2015-08-11 | — | — | US | disclosed |
| US-9101596-B2 | Cation complexes of insulin compound conjugates, formulations and uses thereof | BIOCON LIMITED (IN) | 2015-08-11 | — | — | US | disclosed |
| US-20100105605-A1 | FATTY ACID FORMULATIONS AND ORAL DELIVERY OF PROTEINS AND PEPTIDES, AND USES THEREOF | RADHAKRISHNAN BALASINGAM | 2010-04-29 | — | — | US | disclosed |
| US-20100105605-A1 | FATTY ACID FORMULATIONS AND ORAL DELIVERY OF PROTEINS AND PEPTIDES, AND USES THEREOF | RADHAKRISHNAN BALASINGAM | 2010-04-29 | — | — | US | disclosed |
| US-7605123-B2 | Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof | BIOCON LTD. (IN) | 2009-10-20 | — | — | US | disclosed |
| US-7605123-B2 | Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof | BIOCON LTD. (IN) | 2009-10-20 | — | — | US | disclosed |
| US-7605123-B2 | Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof | BIOCON LTD. (IN) | 2009-10-20 | — | — | US | disclosed |
| EP-1773878-A2 | INSULIN-OLIGOMER CONJUGATES, FORMULATIONS AND USES THEREOF | Nobex Corporation (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006014673-A2 | INSULIN-OLIGOMER CONJUGATES, FORMULATIONS AND USES THEREOF | NOBEX CORPORATION (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060018874-A1 | Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof | BIOCON LIMITED (IN) | 2006-01-26 | — | — | US | disclosed |
| US-20060019874-A1 | Cation complexes of insulin compund conjugates, formulation and uses thereof | NOBEX CORPORATION | 2006-01-26 | — | — | US | disclosed |
| US-20060019873-A1 | Cation complexes of insulin compound conjugates, formulations and uses thereof | BIOCON LIMITED (IN) | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019873-A1 | Cation complexes of insulin compound conjugates, formulations and uses thereof | GPR119, INSR, IAPP | HPGD 3925/4885HTT 2890/4885SMN1; SMN2 3078/4885 |
| US-20220233706-A1 | BIOLOGICAL MATERIALS AND USES THEREOF | CD47, LNPEP, TIE1 | HPGD 3338/4885HTT 1929/4885SMN1; SMN2 3169/4885 |
| US-20100105605-A1 | FATTY ACID FORMULATIONS AND ORAL DELIVERY OF PROTEINS AND PEPTIDES, AND USES THEREOF | FABP2, SLC27A1, SLC27A2 | HPGD 4005/4885HTT 1498/4885SMN1; SMN2 1534/4885 |
| US-20060018874-A1 | Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof | FABP2, SLC27A1, SLC27A2 | HPGD 3961/4885HTT 1496/4885SMN1; SMN2 1537/4885 |
| US-20060019874-A1 | Cation complexes of insulin compund conjugates, formulation and uses thereof | INSR, GPR119, IAPP | HPGD 4150/4885HTT 614/4885SMN1; SMN2 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.